CoChat

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Open access
Toth, Peter P., Worthy, Gillian, Gandra, Shravanthi R., Sattar, Naveed, Bray, Sarah, Cheng, Lung‐I., Bridges, Ian, Worth, Gavin M., Dent, Ricardo, Forbes, Carol A., Deshpande, Sohan, Ross, Janine, Kleijnen, Jos, Stroes, Erik S. G. · 2017 · Journal of the American Heart Association
Cited by 92

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Background: The proprotein convertase subtilisin/kexin type 9 ( PCSK 9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol ( LDL ‐C) when added to statin therapy in patients who need additional LDL ‐C reduction. Methods and Results: We conducted a systematic review and network meta‐analysis of randomized trials of lipid‐lowering therapies from database inception through August 2016 (45 058 records retrieved). We found 69 trials of lipid‐lowering therapies that enrolled patients requiring further LDL ‐C reduction while on maximally tolerated medium‐ or high‐intensity statin, of which 15 could be relevant for inclusion in LDL ‐C reduction networks with evolocumab, alirocumab, ezetimibe, and placebo as treatment arms. PCSK 9 inhibitors significantly reduced LDL ‐C by 54% to 74% versus placebo and 26% to 46% versus ezetimibe. There were significant treatment differences for evolocumab 140 mg every 2 weeks at the mean of weeks 10 and 12 versus placebo (−74.1%; 95% credible interval −79.81% to −68.58%), alirocumab 75 mg (−20.03%; 95% credible interval −27.32% to −12.96%), and alirocumab 150 mg (−13.63%; 95% credible interval −22.43% to −5.33%) at ≥12 weeks. Treatment differences were similar in direction and magnitude for PCSK 9 inhibitor monthly dosing. Adverse events were similar between PCSK 9 inhibitors and control. Rates of adverse events were similar between PCSK 9 inhibitors versus placebo or ezetimibe. Conclusions: PCSK 9 inhibitors added to medium‐ to high‐intensity statin therapy significantly reduce LDL ‐C in patients requiring further LDL ‐C reduction. The network meta‐analysis showed a significant treatment difference in LDL ‐C reduction for evolocumab versus alirocumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.116.005367

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

Metadata

Authors
Toth, P. P., Worthy, G., Gandra, S. R., Sattar, N., Bray, S., Cheng, L., Bridges, I., Worth, G. M., Dent, R., Forbes, C. A., Deshpande, S., Ross, J., Kleijnen, J., & Stroes, E. S. G.
Venue
Journal of the American Heart Association
Published
2017-10-11
Volume
6
Issue
10
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2761079932
Cited by
92
References
24
FWCI
2.42
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.